120 related articles for article (PubMed ID: 26394271)
41. Biologic agents for rheumatoid arthritis: 2008 and beyond.
Sweiss NJ; Hushaw LL
J Infus Nurs; 2009; 32(1 Suppl):S4-17; quiz S19-24. PubMed ID: 19142153
[TBL] [Abstract][Full Text] [Related]
42. [Anti-TNF alpha in the treatment of rheumatoid arthritis and ankylosing spondylitis].
Lanfant-Weybel K; Lequerré T; Vittecoq O
Presse Med; 2009 May; 38(5):774-87. PubMed ID: 19327945
[TBL] [Abstract][Full Text] [Related]
43. Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis.
Torre-Cisneros J; Del Castillo M; Castón JJ; Castro MC; Pérez V; Collantes E
Rheumatology (Oxford); 2005 Sep; 44(9):1132-5. PubMed ID: 15927999
[TBL] [Abstract][Full Text] [Related]
44. Mortality in patients with rheumatoid arthritis-associated interstitial lung disease treated with an anti-tumor necrosis factor agent.
Koo BS; Hong S; Kim YJ; Kim YG; Lee CK; Yoo B
Korean J Intern Med; 2015 Jan; 30(1):104-9. PubMed ID: 25589842
[TBL] [Abstract][Full Text] [Related]
45. Safety issues and concerns of new immunomodulators in rheumatology.
Selmi C; Ceribelli A; Naguwa SM; Cantarini L; Shoenfeld Y
Expert Opin Drug Saf; 2015 Mar; 14(3):389-99. PubMed ID: 25518908
[TBL] [Abstract][Full Text] [Related]
46. Delayed treatment with tumor necrosis factor inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs shows an excellent effect in patients with very early rheumatoid arthritis with poor prognosis factors.
Kita J; Tamai M; Arima K; Nakashima Y; Suzuki T; Kawashiri SY; Okada A; Koga T; Yamasaki S; Nakamura H; Origuchi T; Aramaki T; Nakashima M; Fujikawa K; Tsukada T; Ida H; Aoyagi K; Uetani M; Eguchi K; Kawakami A
Mod Rheumatol; 2012 Apr; 22(2):195-201. PubMed ID: 21898075
[TBL] [Abstract][Full Text] [Related]
47. Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy.
Aaltonen KJ; Joensuu JT; Virkki L; Sokka T; Aronen P; Relas H; Valleala H; Rantalaiho V; Pirilä L; Puolakka K; Uusitalo T; Blom M; Konttinen YT; Nordström D
J Rheumatol; 2015 Mar; 42(3):372-8. PubMed ID: 25593230
[TBL] [Abstract][Full Text] [Related]
48. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events.
Leombruno JP; Einarson TR; Keystone EC
Ann Rheum Dis; 2009 Jul; 68(7):1136-45. PubMed ID: 18753157
[TBL] [Abstract][Full Text] [Related]
49. Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis.
Johnston SS; Turpcu A; Shi N; Fowler R; Chu BC; Alexander K
Semin Arthritis Rheum; 2013 Aug; 43(1):39-47. PubMed ID: 23453683
[TBL] [Abstract][Full Text] [Related]
50. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis.
Salliot C; Finckh A; Katchamart W; Lu Y; Sun Y; Bombardier C; Keystone E
Ann Rheum Dis; 2011 Feb; 70(2):266-71. PubMed ID: 21097801
[TBL] [Abstract][Full Text] [Related]
51. Conventional, biological disease-modifying anti-rheumatic drugs and Janus kinase inhibitors and varicella zoster virus.
Atzeni F; Gozza F; Riva A; Alciati A; Galloway J
Expert Opin Pharmacother; 2023 Apr; 24(6):679-689. PubMed ID: 36946287
[TBL] [Abstract][Full Text] [Related]
52. Immune evasion during varicella zoster virus infection of keratinocytes.
Black AP; Jones L; Malavige GN; Ogg GS
Clin Exp Dermatol; 2009 Dec; 34(8):e941-4. PubMed ID: 19549245
[TBL] [Abstract][Full Text] [Related]
53. Rate of serious infections in patients with rheumatoid arthritis receiving tumor necrosis factor (TNF)-alpha antagonist: a prospective observational study.
Talarico R; Stagnaro C; Ferrari C; Pepe P; Bazzichi L; Bombardieri S
Joint Bone Spine; 2014 Jul; 81(4):378-9. PubMed ID: 24962976
[No Abstract] [Full Text] [Related]
54. Reply to Talarico et al.'s comment: "Rate of serious infections in patients with rheumatoid arthritis receiving tumor necrosis factor (TNF)-alpha antagonist: a prospective observational study".
Che H; Lukas C; Morel J; Combe B
Joint Bone Spine; 2014 Jul; 81(4):379-80. PubMed ID: 24962980
[No Abstract] [Full Text] [Related]
55. Switching anti-TNF-alpha agents: what is the evidence?
Erickson AR; Mikuls TR
Curr Rheumatol Rep; 2007 Oct; 9(5):416-20. PubMed ID: 17915098
[TBL] [Abstract][Full Text] [Related]
56. Treatment considerations in patients with concomitant viral infection and autoimmune rheumatic diseases.
Louthrenoo W
Best Pract Res Clin Rheumatol; 2015 Apr; 29(2):319-42. PubMed ID: 26362747
[TBL] [Abstract][Full Text] [Related]
57. Immunology: Zoster vaccine and biologic agents: time to question a paradigm?
Bongartz T; Orenstein R
Nat Rev Rheumatol; 2012 Nov; 8(11):636-8. PubMed ID: 23027029
[No Abstract] [Full Text] [Related]
58. Cervical cancer risk with the use of tumour necrosis factor inhibitors in rheumatoid arthritis: to worry or not to worry?
Singh JA
Ann Rheum Dis; 2016 Jul; 75(7):1265-7. PubMed ID: 26951640
[No Abstract] [Full Text] [Related]
59. Increased susceptibility to pneumonia due to tumour necrosis factor inhibition and prospective immune system rescue
Ha R; Keynan Y; Rueda ZV
Front Cell Infect Microbiol; 2022; 12():980868. PubMed ID: 36159650
[TBL] [Abstract][Full Text] [Related]
60. Perioperative management of immunosuppression in rheumatic diseases--what to do?
Härle P; Straub RH; Fleck M
Rheumatol Int; 2010 Jun; 30(8):999-1004. PubMed ID: 20033813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
